Shawn Garbett
Department of Biostatistics
Vanderbilt University School of Medicine
2525 West End Ave.
Nashville, TN 37203
Tel: 615.397.8737
E-Mail: 
Institutional Affiliation: Vanderbilt University
NBER Working Papers and Publications
April 2018 | The Value of Pharmacogenomic Information
with John A. Graves, Zilu Zhou, Josh F. Peterson
in Economic Dimensions of Personalized and Precision Medicine, Ernst R. Berndt, Dana P. Goldman, and John W. Rowe, editor
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that predicts drug response, reimbursement for genetic testing among health systems and payers remains uneven. In large measure this is because the cascading impacts of genetic testing on individual and provider incentives and behavior, as well as downstream health care spending and outcomes, remain poorly understood. In this study, we couple evidence from a real-world implementation of pharmacogenomic testing with a discrete event simulation model. We use this framework to evaluate the cost-effectiveness of va... |
December 2017 | The Value of Pharmacogenomic Information
with John A. Graves, Zilu Zhou, Josh Peterson: w24134
Pharmacogenomics, or the application of genetic testing to guide drug selection and/or dosing, is often cited as integral to the vision of how precision medicine can be integrated into routine clinical practice. Yet despite a growing base of scientific discovery on genetic variation that predicts drug response, reimbursement for genetic testing among health systems and payers remains uneven. In large measure this is because the cascading impacts of genetic testing on individual and provider incentives and behavior, as well as downstream health care spending and outcomes, remain poorly understood. In this study, we couple evidence from a real-world implementation of pharmacogenomic testing with a discrete event simulation model. We use this framework to evaluate the cost-effectiveness of... |
|
|